FINWIRES · TerminalLIVE
FINWIRES

Update: EMCOR Shares Rise After Higher Q2 Results, 2026 Guidance Boost

By

(Updates with the latest stock movement in the first paragraph and headline.)

EMCOR (EME) shares were up over 18% in Thursday trading after the company reported higher Q2 results and raised its 2026 guidance.

The company reported Q2 earnings Thursday of $9.06 per diluted share, up from $6.72 a year earlier.

Analysts polled by FactSet expected $7.20.

Revenue for the quarter ended June 30 was $5.15 billion, up from $4.3 billion a year earlier.

Analysts surveyed by FactSet expected $4.71 billion.

For 2026, the company raised diluted EPS guidance to $32 to $33.25 from $28.25 to $29.75 previously and increased its revenue forecast to $20 billion to $20.5 billion from $18.5 billion to $19.25 billion. Analysts polled by FactSet expect EPS of $29.32 and revenue of $19 billion.

Price: $796.96, Change: $+124.48, Percent Change: +18.51%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT